Premium
Clobazam in the treatment of anxiety
Author(s) -
Beaumont George
Publication year - 1995
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470100704
Subject(s) - clobazam , lorazepam , anxiolytic , bromazepam , anxiety , benzodiazepine , chlordiazepoxide , diazepam , anti anxiety agents , medicine , generalized anxiety disorder , alprazolam , anesthesia , oxazepam , temazepam , sedative , psychology , psychiatry , epilepsy , receptor
The efficacy and safety of clobazam in the treatment of generalized anxiety disorders, anxiety neurosis and anxiety secondary to underlying physical disease were reviewed. Clobazam 30–80 mg daily was shown to be at least as effective as equipotent doses of diazepam, lorazepam, dipotassium clorazepate, chlordiazepoxide, bromazepam and alprazolam, with the maximum anxiolytic response seen one to two weeks after commencing treatment. Clobazam was generally well tolerated. In studies using moderate and equipotent dose regimens, subjective drowsiness was reported less frequently with clobazam than with diazepam or lorazepam. Furthermore, compared with the 1,4‐benzodiazepine tranquillizers, there was no objective evidence of any sedative or amnestic effects or impairment of psychomotor function with clobazam. Clobazam would therefore appear to be a useful agent in the treatment of outpatients and patients in general practice with anxiety disorders.